File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Cerebral protection in traumatic brain injury

TitleCerebral protection in traumatic brain injury
Authors
KeywordsBrain Injury
Neuroprotection
Issue Date2005
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/ASH
Citation
Surgical Practice, 2005, v. 9 n. 4, p. 122-125 How to Cite?
AbstractWith advances in the understanding of the pathophysiology of traumatic brain injury, many novel cerebroprotective measures have been developed. Many of them have undergone preclinical trials and have shown promising results, but the results have not translated into clinical benefits. Evidence of these cerebroprotective measures including NMDA-receptor antagonist, steroids, free radial scavengers, nimodipine, ziconotide, bradykinin receptor antagonist and dexanabinol has been reviewed. Problems encountered in clinical studies of traumatic brain injury are mainly related to the heterogenicity of traumatic brain injury and the design of clinical studies. Given all these difficulties, clear benefit of these measures cannot be shown and an optimum treatment strategy has yet been developed. © 2005 Blackwell Publishing Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/172913
ISSN
2013 Impact Factor: 0.172
2015 SCImago Journal Rankings: 0.121
References

 

DC FieldValueLanguage
dc.contributor.authorTse, YHen_US
dc.contributor.authorLeung, GKKen_US
dc.contributor.authorFan, YWen_US
dc.date.accessioned2012-10-30T06:25:46Z-
dc.date.available2012-10-30T06:25:46Z-
dc.date.issued2005en_US
dc.identifier.citationSurgical Practice, 2005, v. 9 n. 4, p. 122-125en_US
dc.identifier.issn1744-1625en_US
dc.identifier.urihttp://hdl.handle.net/10722/172913-
dc.description.abstractWith advances in the understanding of the pathophysiology of traumatic brain injury, many novel cerebroprotective measures have been developed. Many of them have undergone preclinical trials and have shown promising results, but the results have not translated into clinical benefits. Evidence of these cerebroprotective measures including NMDA-receptor antagonist, steroids, free radial scavengers, nimodipine, ziconotide, bradykinin receptor antagonist and dexanabinol has been reviewed. Problems encountered in clinical studies of traumatic brain injury are mainly related to the heterogenicity of traumatic brain injury and the design of clinical studies. Given all these difficulties, clear benefit of these measures cannot be shown and an optimum treatment strategy has yet been developed. © 2005 Blackwell Publishing Ltd.en_US
dc.languageengen_US
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/ASHen_US
dc.relation.ispartofSurgical Practiceen_US
dc.subjectBrain Injuryen_US
dc.subjectNeuroprotectionen_US
dc.titleCerebral protection in traumatic brain injuryen_US
dc.typeArticleen_US
dc.identifier.emailLeung, GKK: gilberto@hkucc.hku.hken_US
dc.identifier.authorityLeung, GKK=rp00522en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1744-1633.2005.00271.xen_US
dc.identifier.scopuseid_2-s2.0-33745247396en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33745247396&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume9en_US
dc.identifier.issue4en_US
dc.identifier.spage122en_US
dc.identifier.epage125en_US
dc.publisher.placeAustraliaen_US
dc.identifier.scopusauthoridTse, YH=14020824300en_US
dc.identifier.scopusauthoridLeung, GKK=35965118200en_US
dc.identifier.scopusauthoridFan, YW=7403492523en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats